Lucent (@UseLucentHQ) header
Lucent (@UseLucentHQ) profile picture

Lucent

@UseLucentHQ

Biopharma Prediction Markets. Backed by @alliance

 NYC
lucent.markets
Joined March 2026
  • Tweets33
  • Following61
  • Followers336
$MRNA won FDA approval for its mRNA flu vaccine, marking the first approved mRNA flu shot in the U.S.
1
2
305
$LLY $NVO are back in focus as the obesity race tightens, with Novo clawing back ground on Lilly ahead of Lilly earnings.
1
593
$REPL said an FDA advisory panel backed RP1 for advanced melanoma, after the agency had previously rejected the therapy twice.
1
2
877
Full $REPL review context, prior agency overhang, and ongoing analyst-desk framing at lucentintel.com
2
264
$REPL sentiment into the RP1 panel looks cautious. Biotech desks are treating the setup less as a comeback story and more as another test of how little patience FDA has for messy efficacy packages after a rough week for adcom-stage names. We're mapping the FDA-panel, efficacy-package, and analyst-desk axes around $REPL at lucentintel.com
2
325
$CAPR's FDA advisory committee on deramiocel in Duchenne is underway as Capricor heads into a near-term PDUFA. $REPL's own adcomm follows Thursday.
1
868
$CAPR fell after FDA reviewers said the company’s Duchenne cell therapy did not meet a Phase 3 trial’s objectives ahead of a closely watched adcomm and PDUFA next month.
3
386
$AZN said it does not plan to ramp up dealmaking after the Wainua failure, with earnings due in the coming days.
3
172
$LLY $SNY-backed Scribe popping in its IPO is less about one cap table than a broader signal: public investors are still willing to pay for gene-editing exposure when the strategic sponsorship is strong.
1
2
169
On $AMGN and Tavneos, biotech Twitter reads this as classic Amgen: litigate, reanalyze, and keep pressing every regulatory angle when a commercial asset is at risk. Full $AMGN regulatory timeline, withdrawal-risk context, and desk sentiment around Tavneos at lucentintel.com
1
8
172
The peptide fight is turning into a second front in obesity: not just who wins scripts, but who controls supply at the edge of FDA policy. $LLY $NVO and compounders all have exposure to where the agency lands.
1
5
743
$LLY $NVO obesity market structure now runs through policy, compounding, and channel access at the same time. We’re mapping the regulatory, supply, and commercial axes at lucentintel.com
1
103
$LLY’s retatrutide is turning into a filing story, not just a data story. Two more Phase 3 obesity wins push the focus from efficacy magnitude to label scope, tolerability, and how regulators frame the triple-agonist category.
3
3
272
$LLY obesity filing setup — we're tracking label-shaping endpoints, tolerability readthroughs, and competitive positioning across the incretin field at lucentintel.com
2
47
On $ARWR vs $IONS, biotech Twitter isn't reading today's data as a simple winner-take-all. The emerging view is efficacy may favor Ionis more than expected, while Arrowhead's path to share likely depends on safety, access, and execution.
1
5
538
Full $ARWR/$IONS context now spans efficacy deltas, safety interpretation, launch positioning, and takeover/speculation spillover in the analyst and buy-side conversation at lucentintel.com
2
124
$NVO sued $LLY, alleging Lilly’s GLP-1 ads are deceptive and rely on outdated clinical trial data to overstate obesity and diabetes drug performance.
1
5
601
$BMY is expanding its Nvidia partnership to build what it calls the most powerful AI factory in life sciences, aimed at speeding internal drug discovery and development. biopharmadive.com/news/brist…
Bristol Myers to build ‘powerful’ AI factory; Samsung Biologics bids for peptide maker

Bristol Myers to build ‘powerful’ AI factory; Samsung Biologics bids for peptide maker

Bristol Myers is the third pharmaceutical company to recently seek Nvidia’s help building a large AI data center. Elsewhere, a Novartis kidney drug gained a leg up on competitors.

biopharmadive.com
2
291
Lucent retweeted
AX1 (@ax1vc) profile picture
AX1
@ax1vcMay 25
X Space - Thursday, May 28, 5PM UTC AX1 is partnering with @UseLucentHQ Lucent is an Alliance alum building in one of the harder corners of investing: biopharma. Join us with @JulianMalinak, co-founder of Lucent, to discuss why biopharma may need a much better investing interface. This market moves on FDA decisions, trial readouts, filings, expert debates, and small signals most investors never learn how to read. A lot of the information is technically public, but public does not mean understandable. It is scattered and hard to turn into a view before the market already reacts. Lucent is building for that gap. AI-native biopharma intelligence that helps investors track catalysts, understand company and asset-level context, and see why a signal may matter. Set a reminder. xitter.gq/i/spaces/1DGleeeQdmRJL

184
213
6
313
95,094
Stay tuned...
7
2
41
885
Load more